SL
PCRX icon

Salomon & Ludwin’s Pacira BioSciences PCRX Stock Holding History

Salomon & Ludwin’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.38K Hold
335
– – ﹤0.01% 1660
2026
Q1 		$7.61K Buy
335
+89
+36% +$1.98K ﹤0.01% 1625
2025
Q4 		$6.17K Sell
246
-88
-26% -$2.09K ﹤0.01% 1699
2025
Q3 		$8.3K Buy
+334
New +$8.2K ﹤0.01% 1448

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Salomon & Ludwin's PCRX Position: Q2 2026 in Review

Salomon & Ludwin held its Pacira BioSciences (PCRX) position steady in Q2 2026 at 335 shares worth $8.38K. The position accounts for ﹤0.01% of the portfolio, ranked #1660.

Salomon & Ludwin first reported a position in PCRX in Q3 2025 and has held it in 4 quarters since. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Salomon & Ludwin held 335 shares of Pacira BioSciences worth $8.38K as of Q2 2026.
  • Salomon & Ludwin left its Pacira BioSciences share count unchanged in Q2 2026.
  • Pacira BioSciences made up ﹤0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #1660 holding.
  • Salomon & Ludwin first reported a position in Pacira BioSciences in Q3 2025 and has held it in 4 quarters since.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.